Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $49 PT on CVS Caremark Corporation

Related CVS
Early Global News: Record Online Sales, 400% Jump In Tinder Users, China Experiences Worst Drop In Months
CVS Health Announces Formulary and Therapy Strategy for PCSK9 Inhibitors
The Catalyst That Antares Pharma Really Needs To See Growth (Seeking Alpha)

In a report published Friday, Bank of America Merrill Lynch reiterated its Buy rating and $49.00 price target on CVS Caremark Corporation (NYSE: CVS).

BofA Merrill Lynch noted, “According to media reports, CVS will buy an 80% stake in Brazilian retail pharmacy chain Onofre for $313 million, plus assumed debt. The deal adds 44 stores (the eighth-largest chain in Brazil) in a high-growth region with rapidly expanding health care coverage. However, we maintain our 2013 EPS estimate ($3.57) at this time, on the relatively small investment size and what we expect are few operating synergies.”

CVS Caremark Corporation closed on Thursday at $46.71.

Latest Ratings for CVS

Nov 2015JP MorganMaintainsOverweight
Nov 2015OppenheimerMaintainsOutperform
Aug 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings


Related Articles (CVS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters